Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Deferred Taxes: 2014-2021

Historic Deferred Taxes for Enanta Pharmaceuticals (ENTA) over the last 8 years, with Sep 2021 value amounting to $345,000.

  • Enanta Pharmaceuticals' Deferred Taxes rose 1363.63% to $15.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $10.6 million, marking a year-over-year increase of 438.05%. This contributed to the annual value of $345,000 for FY2021, which is 96.75% down from last year.
  • According to the latest figures from FY2021, Enanta Pharmaceuticals' Deferred Taxes is $345,000, which was down 96.75% from $10.6 million recorded in FY2020.
  • In the past 5 years, Enanta Pharmaceuticals' Deferred Taxes ranged from a high of $10.6 million in FY2020 and a low of -$3.1 million during FY2019.
  • In the last 3 years, Enanta Pharmaceuticals' Deferred Taxes had a median value of $345,000 in 2021 and averaged $2.6 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Deferred Taxes slumped by 268.89% in 2019, and later surged by 438.05% in 2020.
  • Over the past 5 years, Enanta Pharmaceuticals' Deferred Taxes (Yearly) stood at -$1.7 million in 2017, then spiked by 212.33% to $1.9 million in 2018, then plummeted by 268.89% to -$3.1 million in 2019, then spiked by 438.05% to $10.6 million in 2020, then tumbled by 96.75% to $345,000 in 2021.